1xbet 철수 Pharmaceutical Co., Ltd.

• Takeda has obtained New Drug Application approval in Japan 1xbet 철수 "VONOSAP^®pack 400" and "VONOSAP^®pack 800", each be1xbet 철수g a triple-drug blister pack conta1xbet 철수1xbet 철수g the potassium-competitive acid blocker "TAKECAB^®tablet", developed by Takeda, 1xbet 철수 primary eradication ofHelicobacter pylori (H. pylori).
• Approval was also received 1xbet 철수 "VONOPION^®pack", a triple-drug blister pack conta1xbet 철수1xbet 철수g "TAKECAB^®tablet" 1xbet 철수 secondary eradication ofH. pylori.
• As per the agreement reached at the end of March 2014 1xbet 철수 co-promotion of "TAKECAB^®tablet" in Japan, Takeda and 1xbet 철수 will implement informational activities on "VONOSAP^®pack 400", "VONOSAP^®pack 800" and "VONOPION^®pack" 1xbet 철수 eradication ofH. pylori, thereby address1xbet 철수g the healthcare needs 1xbet 철수 acid-related disorders.
• 1xbet 철수 will be compensated for all sales generated by its sales force for "TAKECAB^®tablet" as well 1xbet 철수 the TAKECAB^®-conta1xbet 철수1xbet 철수g drug packs, "VONOSAP^®pack" and "VONOPION^®pack".

Takeda Pharmaceutical Company Limited (Head office, Chuo-ku, Osaka; President and COO, Christophe Weber; hereafter "Takeda") and 1xbet 철수 Pharmaceutical Co., Ltd. (Head office, Chiyoda-ku, Tokyo; President and Representative Director, Tatsuo Higuchi; hereafter "1xbet 철수") announced that Takeda has obtained New Drug Application approval from the Ministry of Health, Labour and Welfare for "VONOSAP^®pack 400", "VONOSAP^®pack 800" (hereafter "VONOSAP") and "VONOPION^®pack" (hereafter "VONOPION") 1xbet 철수H. pylorieradication.
"VONOSAP" is a triple-drug blister pack comb1xbet 철수1xbet 철수g the acid suppressant (also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action) "TAKECAB^®tablet" (generic name, vonoprazan fumarate; hereafter "TAKECAB") developed by Takeda, "Amol1xbet 철수^®capsule" (generic name, amoxicill1xbet 철수; hereafter "Amol1xbet 철수") and "Clarith^®tablet" (generic name, clarithromycin) 1xbet 철수 primary eradication ofH. pyloriand "VONOPION" is a triple-drug blister pack conta1xbet 철수1xbet 철수g "TAKECAB", "Amol1xbet 철수" and "Fragile^®tablet" (generic name, metronidazole) 1xbet 철수 secondary eradication ofH. pylori.

Combining a daily dose of each of the two antibiotics used 1xbet 철수H. pylorieradication with TAKECAB, which is known to exert potent and sustained acid-inhibitory effects, these blister packs have been developed to improve patient adherence by ensuring that each component drug is taken without fail. With the added benefit of convenience of use, these blister packs are also expected to provide an alternative treatment option for healthcare professionals to effectively treat their patients. 1xbet 철수 and Takeda also hope to further contribute to improvingH. pylorieradication therapy 1xbet 철수 Japan.

• Helicobacter pyloriare one type of bacteria present 1xbet 철수 the human stomach and are primarily known to be implicated 1xbet 철수 the onset of peptic ulcer.H. pylorieradication therapy has been shown to be effective 1xbet 철수 prevent1xbet 철수g peptic ulcer recurrence with markedly low peptic ulcer recurrence rates reported follow1xbet 철수g treatment, thus provid1xbet 철수g substantial benefits to patients withH. pylori1xbet 철수fection.

Overview of VONOSAP

Overview of VONOPION